Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

CAR-T ¼¼Æ÷ Ä¡·áÁ¦

Chimeric Antigen Receptor-T Cell Therapy

´ëÇѳ»°úÇÐȸÁö 2022³â 97±Ç 4È£ p.229 ~ 237
º¯ÀÚ¹Î, À±¼º¼ö,
¼Ò¼Ó »ó¼¼Á¤º¸
º¯ÀڹΠ( Byun Ja-Min ) - Seoul National University College of Medicine Department of Internal Medicine
À±¼º¼ö ( Yoon Sung-Soo ) - Seoul National University College of Medicine Department of Internal Medicine

Abstract


Chimeric antigen receptor (CAR) T-cell therapy constitutes a revolutionary advancement in personalized cancer treatment.
During this treatment, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen.
CAR-T cells are then expanded for clinical use and infused back into the patient's body to attack cancer. CAR-T cells have produced remarkable clinical responses with B-cell malignancies. However, CAR-T cells therapy is not without problems. Barriers to effective CAR-T cells therapy include severe life-threatening toxicities and modest anti-tumor activity. In this review, we introduce the concept of CAR-T cells therapy, currently available CAR-T cells therapy options, and how to deal with adverse events.

Ű¿öµå

Chimeric antigen receptor; CAR-T cell therapy; Lymphoma; Multiple myeloma

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸